Bloom X³ Inc. extends its sincere congratulations to Dr. Joe Bolen, Advisor to Bloom X³ and Chief Executive Officer of Orna Therapeutics, and to the entire Orna team on the announced acquisition by Eli Lilly and Company.
According to the official announcement, the transaction is valued at up to $2.4 billion, representing a landmark milestone in next-generation RNA platform technologies and in vivo cell therapy innovation. The acquisition underscores the scientific strength, scalability, and strategic relevance of Orna’s proprietary circular RNA platform.
Orna Therapeutics has built a transformative technological foundation that expands the frontier of programmable cell therapies. This acquisition validates both the scientific rigor and long-term commercial vision behind Orna’s platform.
Dr. Bolen’s global leadership and experience continue to provide strategic perspective to Bloom X³ in advancing cross-border life sciences innovation. This transaction exemplifies how cutting-edge science, global collaboration, and disciplined execution converge to create substantial enterprise value.
Bloom X³ remains committed to accelerating cross-border partnerships and building globally competitive life sciences platforms.
For full details, please refer to the official announcement:
https://www.ornatx.com/lilly-to-acquire-orna-therapeutics-to-advance-cell-therapies/
